228 related articles for article (PubMed ID: 28450892)
21. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study.
Uitdehaag B; Constantinescu C; Cornelisse P; Jeffery D; Kappos L; Li D; Sandberg-Wollheim M; Traboulsee A; Verdun E; Rivera V
Ther Adv Neurol Disord; 2011 Jan; 4(1):3-14. PubMed ID: 21339904
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II).
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Picconi O; Cilia S; Cottone S; Grimaldi LM;
Qual Life Res; 2012 Sep; 21(7):1111-21. PubMed ID: 21953022
[TBL] [Abstract][Full Text] [Related]
23. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
Walter E; Berger T; Bajer-Kornek B; Deisenhammer F
J Med Econ; 2019 Mar; 22(3):226-237. PubMed ID: 30522373
[TBL] [Abstract][Full Text] [Related]
24. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
25. Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15.
Kappos L; Kuhle J; Multanen J; Kremenchutzky M; Verdun di Cantogno E; Cornelisse P; Lehr L; Casset-Semanaz F; Issard D; Uitdehaag BM
J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1202-7. PubMed ID: 26374702
[TBL] [Abstract][Full Text] [Related]
26. The STAR Study: a real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon β-1a in patients with relapsing multiple sclerosis.
Hupperts R; Ghazi-Visser L; Martins Silva A; Arvanitis M; Kuusisto H; Marhardt K; Vlaikidis N;
Clin Ther; 2014 Dec; 36(12):1946-1957. PubMed ID: 24811754
[TBL] [Abstract][Full Text] [Related]
27. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
28. Utilization of peginterferon-β-1a in the real-world practice for relapsing-remitting multiple sclerosis.
Moccia M; Santoni L; Vaccari I; Affinito G; Caliendo D; Rubba F; Lanzillo R; Triassi M; Brescia Morra V; Palladino R
Eur Rev Med Pharmacol Sci; 2024 Jan; 28(1):411-418. PubMed ID: 38235893
[TBL] [Abstract][Full Text] [Related]
29. Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results.
Wilken J; Traboulsee A; Nelson F; Ionete C; Kolind S; Fratto T; Kane R; Gandhi R; Rawlings AM; Roesch N; Ozog MA; DeLuca J;
Mult Scler Relat Disord; 2023 May; 73():104677. PubMed ID: 37028124
[TBL] [Abstract][Full Text] [Related]
30. [Information processing speed and influential factors in multiple sclerosis].
Zhang ML; Xu EH; Dong HQ; Zhang JW
Zhonghua Yi Xue Za Zhi; 2016 Apr; 96(15):1173-7. PubMed ID: 27117362
[TBL] [Abstract][Full Text] [Related]
31. Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study.
Ernst FR; Barr P; Elmor R; Wong SL
Curr Med Res Opin; 2017 Dec; 33(12):2099-2106. PubMed ID: 28906152
[TBL] [Abstract][Full Text] [Related]
32. Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
Kleinschnitz C; Niemczyk G; Rehberg-Weber K; Wernsdörfer C
Int J Mol Sci; 2015 Jul; 16(7):15271-86. PubMed ID: 26154767
[TBL] [Abstract][Full Text] [Related]
33. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M; Ridley B; Minozzi S; Del Giovane C; Peryer G; Piggott T; Foschi M; Filippini G; Tramacere I; Baldin E; Nonino F
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD011381. PubMed ID: 38174776
[TBL] [Abstract][Full Text] [Related]
34. Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves.
Liu C; Blumhardt LD
J Neurol Neurosurg Psychiatry; 1999 Oct; 67(4):451-6. PubMed ID: 10486390
[TBL] [Abstract][Full Text] [Related]
35. Peginterferon beta-1a reduces disability worsening in relapsing-remitting multiple sclerosis: 2-year results from ADVANCE.
Newsome SD; Kieseier BC; Liu S; You X; Kinter E; Hung S; Sperling B
Ther Adv Neurol Disord; 2017 Jan; 10(1):41-50. PubMed ID: 28450894
[TBL] [Abstract][Full Text] [Related]
36. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297
[TBL] [Abstract][Full Text] [Related]
37. Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS).
Achtnichts L; Zecca C; Findling O; Kamm CP; Mueller S; Kuhle J; Lutterotti A; Gobbi C; Viviani C; Villiger-Borter E; Nedeltchev K
BMJ Neurol Open; 2023; 5(1):e000304. PubMed ID: 36727105
[TBL] [Abstract][Full Text] [Related]
38. Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies.
Hunter SF; Aburashed RA; Alroughani R; Chan A; Dive D; Eichau S; Kantor D; Kim HJ; Lycke J; Macdonell RAL; Pozzilli C; Scott T; Sharrack B; Wiendl H; Chung L; Daizadeh N; Baker DP; Vermersch P;
Neurol Ther; 2021 Dec; 10(2):803-818. PubMed ID: 34165694
[TBL] [Abstract][Full Text] [Related]
39. Olfactory Dysfunction in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Disease-Modifying Therapies.
Wnuk M; Drabik L; Marona M; Szaleniec J; Bryll A; Karcz P; Kolasinska J; Kolasinska M; Ziekiewicz M; Skladzien J; Popiela T; Slowik A
Ear Nose Throat J; 2022 Dec; 101(10):640-644. PubMed ID: 33236917
[TBL] [Abstract][Full Text] [Related]
40. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]